The first ready-to-use liquid neuromodulator just took a real step toward U.S. shelves. On February 2, the FDA accepted Galderma resubmitted application for RelabotulinumtoxinA, the toxin known abroad as Relfydess.
On February 2, 2026, Galderma announced that the FDA accepted its resubmitted Biologics License Application for RelabotulinumtoxinA, the ready-to-use liquid neuromodulator sold abroad as Relfydess, for frown lines and crow feet in adults. Acceptance means the application is complete enough for review; it is not the same as approval, and the product remains investigational in the U.S.
Galderma next-generation botulinum toxin took a meaningful step toward the U.S. market in early February.
RelabotulinumtoxinA is notable because it is formulated as a ready-to-use liquid, unlike the powdered toxins that require mixing before injection.
On February 2, 2026, Galderma confirmed the FDA accepted the resubmitted Biologics License Application (BLA) for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow feet) in adults. The filing is backed by the READY clinical trial program, four phase 3 trials enrolling more than 1,900 participants, with reported onset as early as day 1 and durability up to six months. The product is already marketed in more than 20 countries, including the European Union, the United Kingdom, parts of Asia, and Australia, under the brand Relfydess.
The acceptance follows a 2023 Complete Response Letter that flagged deficiencies limited to chemistry, manufacturing, and controls (CMC), not safety or efficacy. Galderma said it worked with the FDA to adjust its manufacturing process before resubmitting. Crucially, BLA acceptance only means the application is sufficiently complete for substantive review; it is not an approval, and RelabotulinumtoxinA remains an investigational biologic in the United States pending the FDA decision.
For consumers, this is an early signal that a differentiated toxin, liquid and ready-to-use, may eventually reach U.S. practices, potentially adding choice in a category long dominated by powdered type-A products. But timing is uncertain: acceptance starts the review clock rather than ending it, and no U.S. availability date follows automatically. Patients should treat international approval and U.S. investigational status as separate facts.
What to watch next is the FDA review timeline. If the application is ultimately approved, the United States would gain its first ready-to-use liquid neuromodulator, adding a new option in a category long served by powdered type-A toxins. Watch for a target decision window and whether any eventual U.S. labeling mirrors the frown-line and crow-feet indications already cleared abroad. None of that is assured, acceptance only starts substantive review, so international approval and U.S. status should be tracked as separate facts.